The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Abstract
OBJECTIVE: We wished to develop a highly selective positron emission tomography (PET) imaging agent targeting PHF-tau in human Alzheimer's disease (AD) brains. METHODS: To screen potential tau binders, human AD brain sections were used as a source of native paired helical filament (PHF)-tau and Aβ rather than synthetic tau aggregates or Aβ fibrils generated in vitro to measure the affinity and selectivity of [(18)F]T807 to tau and Aβ. Brain uptake and biodistribution of [(18)F]T807 in mice were also tested. RESULTS: In vitro autoradiography results show that [(18)F]T807 exhibits strong binding to PHF-tau-positive human brain sections. A dissociation constant (Kd) of [(18)F]T807 (14.6 nM) was measured using brain sections from the frontal lobe of AD patients. A comparison of autoradiography and double immunohistochemical staining of PHF-tau and Aβ on adjacent sections demonstrated that [(18)F]T807 binding colocalized with immunoreactive PHF-tau pathology, but did not highlight Aβ plaques. In vivo studies in mice demonstrated that [(18)F]T807 was able to cross the blood-brain barrier and washed out quickly. CONCLUSIONS: [(18)F]T807 demonstrates high affinity and selectivity to PHF-tau as well as favorable in vivo properties, making this a promising candidate as an imaging agent for AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It also has low affinity for amyloid-β and α-synuclein (Xia et al., 2013).”
From Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum (2020) · cites this paper as Xia et al., 2013
In the citing paper
“18F-AV-1451 was originally developed to bind to paired helical filament tau in Alzheimer’s disease (Zhang et al., 2012; Chien et al., 2013; Xia et al., 2013), and has been extensively used in Alzheimer’s and non-Alzheimer’s diseases.”
From Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum (2020) · cites this paper as Xia et al., 2013
In the citing paper
“Imaging biomarkers for cortical tau have become available.19,20”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [20]
In the citing paper
“As expected, in vitro QC-01–175 and T807 displayed a significantly lower affinity for all recombinant immobilized tau forms than the reported KD of T807 for native, aggregated tau filaments from AD brain sections (KD15 nM)”
From Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models (2019) · cites this paper as Xia et al., 2013
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Neurofibrillary lesions develop at specific high-risk sites, and follow a highly characteristic pattern with regard to affected cell types, cell layers, and brain regions, with only minor interindividual variations [30].”
BackgroundYung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Melnick, V. L., & Dubler, N. N. (1985) · Contemporary Issues in Biomedicine, Ethics, and Society · doi:10.1007/978-1-4612-5174-3 · Cited by 1,986
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611
Flagged first, then by citations
1 of the 41 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- 10.1097/00019442-200411000-00004 · DOI
- Zeng Z, 2012, Presented at the Alzheimer's Association International Conference
Cited by
Sorted by citations
Items 101–200 of 608
Tosun, D., Landau, S. M., Aisen, P. S. S., Petersen, R. C., Mintun, M. A., Jagust, W., Weiner, M. W., & Initiative, A. D. N. (2017) · Brain · doi:10.1093/brain/awx046 · Cited by 110
Lemoine, L., Gillberg, P.-G., Svedberg, M. M., Stepanov, V. A., Jia, Z., Huang, J., Nag, S., Tian, H., Ghetti, B. F., Okamura, N., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0325-z · Cited by 113
Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults
Lowe, V. J., Bruinsma, T. J., Wiste, H. J., Min, H.-K., Weigand, S. D., Fang, P., Senjem, M. L., Therneau, T. M., Boeve, B. F., Josephs, K. A., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007728 · Cited by 107
PET Imaging of Neuropathology in Tauopathies: Progressive Supranuclear Palsy
Kepe, V., Bordelon, Y., Boxer, A., Huang, S.-C., Liu, J., Thiede, F. C., Mazziotta, J. C., Mendez, M. F., Donoghue, N., Small, G. W., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130032 · Cited by 106
Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly
Chhatwal, J. P., Schultz, A. P., Marshall, G. A., Boot, B., Gomez-Isla, T., Dumurgier, J., LaPoint, M., Scherzer, C., Roe, A. D., Hyman, B. T., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003050 · Cited by 106
Uzuegbunam, B. C., Librizzi, D., & Yousefi, B. H. (2020) · Molecules · doi:10.3390/molecules25040977 · Cited by 107
Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers
Strafella, A. P., Bohnen, N. I., Perlmutter, J. S., Eidelberg, D., Pavese, N., van Eimeren, T., Piccini, P. P., Politis, M., Thobois, S., Ceravolo, R., et al. (2017) · Movement Disorders · doi:10.1002/mds.26907 · Cited by 110
Revolutionizing Alzheimer's disease and clinical trials through biomarkers
Mattsson, N., Carrillo, M. C., Dean, R. A., Devous, M. D., Nikolcheva, T., Pesini, P., Salter, H., Potter, W. Z., Sperling, R. A., Bateman, R. J., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.001 · Cited by 102
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
Characteristics of Tau and Its Ligands in PET Imaging
Harada, R., Okamura, N., Furumoto, S., Tago, T., Yanai, K., Arai, H., & Kudo, Y. (2016) · Biomolecules · doi:10.3390/biom6010007 · Cited by 104
Kim, Y. J., Park, S., Cho, H., Jang, Y. K., Lee, J. S., Jang, H., Kim, Y., Kim, K. W., Ryu, Y. H., Choi, J. Y., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0975 · Cited by 100
Hu, Z., Chen, P.-H., Li, W., Douglas, T., Hines, J., Liu, Y., & Crews, C. M. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11706 · Cited by 98
[18F]AV‐1451 clustering of entorhinal and cortical uptake in Alzheimer's disease
Whitwell, J. L., Graff‐Radford, J., Tosakulwong, N., Weigand, S. D., Machulda, M. M., Senjem, M. L., Schwarz, C. G., Spychalla, A. J., Jones, D. T., Drubach, D. A., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25142 · Cited by 95
FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
Rizzo, C., Amata, S., Pibiri, I., Pace, A., Buscemi, S., & Piccionello, A. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097728 · Cited by 100
In vivo tau imaging: Obstacles and progress
Villemagne, V. L., & Okamura, N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.013 · Cited by 100
Hansson, O., Grothe, M. J., Strandberg, T. O., Ohlsson, T. G., Hägerström, D., Jögi, J., Smith, R. A., & Schöll, M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00167 · Cited by 102
Frontiers in Probing Alzheimer’s Disease Biomarkers with Fluorescent Small Molecules
Jun, Y. W., Cho, S. W., Jung, J., Huh, Y., Kim, Y. S., Kim, D., & Ahn, K. H. (2019) · ACS Central Science · doi:10.1021/acscentsci.8b00951 · Cited by 96
Frontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations
Spina, S., Schonhaut, D. R., Boeve, B. F., Seeley, W. W., Ossenkoppele, R., O'Neil, J. P., Lazaris, A., Rosen, H. J., Boxer, A. L., Perry, D. C., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003636 · Cited by 96
Comparing 18 F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
Mattsson, N., Smith, R. A., Strandberg, O. T., Palmqvist, S., Schöll, M., Insel, P. S., Hägerström, D., Ohlsson, T. G., Zetterberg, H., Blennow, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000004887 · Cited by 95
Advances in neuroimaging in frontotemporal dementia
Gordón, E., Rohrer, J. D., & Fox, N. C. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13656 · Cited by 104
Shcherbinin, S., Schwarz, A. J., Joshi, A. D., Navitsky, M. A., Flitter, M. L., Shankle, W. R., Devous, M. D., & Mintun, M. A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.170027 · Cited by 93
Murugan, N. A., Nordberg, A., & Ågren, H. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00093 · Cited by 92
Murugan, N., Chiotis, K., Rodriguez-Vieitez, E., Lemoine, L., Ågren, H., & Nordberg, A. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04305-8 · Cited by 82
Human Positron Emission Tomography Neuroimaging
Hooker, J. M., & Carson, R. E. (2019) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-062117-121056 · Cited by 97
Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants
Whitwell, J. L., Tosakulwong, N., Botha, H., Ali, F., Clark, H. M., Duffy, J. R., Utianski, R. L., Stevens, C. A., Weigand, S. D., Schwarz, C. G., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.102152 · Cited by 95
Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer’s disease
Tanner, J. A., Iaccarino, L., Edwards, L., Asken, B. M., Gorno‐Tempini, M. L., Kramer, J. H., Pham, J. Q., Perry, D. C., Possin, K. L., Malpetti, M., et al. (2022) · Brain · doi:10.1093/brain/awac229 · Cited by 91
Carman, A. J., Ferguson, R. W., Cantu, R. C., Comstock, R. D., Dacks, P. A., DeKosky, S. T., Gandy, S., Gilbert, J., Gilliland, C., Gioia, G. A., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.30 · Cited by 92
Gobbi, L. C., Knust, H., Körner, M., Honer, M., Czech, C., Belli, S., Muri, D., Edelmann, M. R., Hartung, T., Erbsmehl, I., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00632 · Cited by 89
Adams, J. N., Lockhart, S. N., Li, L., & Jagust, W. J. (2018) · Cerebral Cortex · doi:10.1093/cercor/bhy078 · Cited by 90
Sala, A., & Perani, D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00617 · Cited by 88
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
Smith, R., Schöll, M., Leuzy, A., Jögi, J., Ohlsson, T., Strandberg, O., & Hansson, O. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04496-0 · Cited by 88
[18F]AV‐1451 tau‐PET and primary progressive aphasia
Josephs, K. A., Martin, P. R., Botha, H., Schwarz, C. G., Duffy, J. R., Clark, H. M., Machulda, M. M., Graff‐Radford, J., Weigand, S. D., Senjem, M. L., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25183 · Cited by 90
Plasma p‐tau immunoassays in clinical research for Alzheimer's disease
Teunissen, C. E., Kolster, R., Triana‐Baltzer, G., Janelidze, S., Zetterberg, H., & Kolb, H. C. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14397 · Cited by 96
Self-citationMolecular imaging in dementia: Past, present, and future
Laforce, R. J., Soucy, J., Sellami, L., Dallaire‐Théroux, C., Brunet, F., Bergeron, D., Miller, B. L., & Ossenkoppele, R. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.06.2855 · Cited by 88
The association between tau PET and retrospective cortical thinning in clinically normal elderly
LaPoint, M. R., Chhatwal, J. P., Sepulcre, J., Johnson, K. A., Sperling, R. A., & Schultz, A. P. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.05.049 · Cited by 84
Fawaz, M. V., Brooks, A. F., Rodnick, M. E., Carpenter, G. M., Shao, X., Desmond, T. J., Sherman, P. S., Quesada, C., Hockley, B. G., Kilbourn, M. R., et al. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500103u · Cited by 87
Gordon, B. A., McCullough, A. A., Mishra, S., Blazey, T., Su, Y., Christensen, J., Dincer, A., Jackson, K., Hornbeck, R. C., Morris, J. C., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.02.003 · Cited by 89
Advances in Alzheimer's disease research over the past two decades
Jack, C. R. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00298-8 · Cited by 83
Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Passamonti, L., Hong, Y. T., Fryer, T. D., Arnold, R., Allinson, K. S. J., Coles, J. P., Aigbirhio, F. I., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316402 · Cited by 84
Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects
Wooten, D., Guehl, N. J., Verwer, E. E., Shoup, T. M., Yokell, D. L., Zubcevik, N., Vasdev, N., ZAFONTE, R. D., Johnson, K. A., Fakhri, G. E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.170910 · Cited by 85
Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography
Wang, Y. T., & Edison, P. (2019) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-019-0962-7 · Cited by 86
Overview of tau PET molecular imaging
Petersen, G. C., Roytman, M., Chiang, G. C.-Y., Li, Y., Gordon, M. L., & Franceschi, A. M. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001035 · Cited by 87
Preclinical Evaluation of18F-JNJ64349311, a Novel PET Tracer for Tau Imaging
Declercq, L., Rombouts, F. J. R., Koole, M. J. B., Fierens, K., Mariën, J., Langlois, X., Andrés, J. I., Schmidt, M. E., Macdonald, G. J., Moechars, D., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.185199 · Cited by 84
Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau
Josephs, K. A. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.04.016 · Cited by 87
Lehmann, M., Madison, C. M., Ghosh, P. M., Miller, Z., Greicius, M. D., Kramer, J. H., Coppola, G., Miller, B. L., Jagust, W. J., Gorno‐Tempini, M. L., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.029 · Cited by 79
Strategies to facilitate the discovery of novel CNS PET ligands
Zhang, L., & Villalobos, A. (2016) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-016-0016-2 · Cited by 80
Test-retest reproducibility for the tau PET imaging agent flortaucipir F 18.
Devous, M. D., Joshi, A. D., Navitsky, M., Southekal, S., Pontecorvo, M. J., Shen, H., Lu, M., Shankle, W. R., Seibyl, J. P., Marek, K., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200691 · Cited by 79
Tetzloff, K. A., Graff-Radford, J., Martin, P. R., Tosakulwong, N., Machulda, M. M., Duffy, J. R., Clark, H. M., Senjem, M. L., Schwarz, C. G., Spychalla, A. J., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170740 · Cited by 78
Ishiki, A., Okamura, N., Furukawa, K., Furumoto, S., Harada, R., Tomita, N., Hiraoka, K., Watanuki, S., Ishikawa, Y., Tago, T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140311 · Cited by 77
In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury
Gorgoraptis, N., Li, L. M., Whittington, A., Zimmerman, K. A., Maclean, L. M., McLeod, C., Ross, E., Heslegrave, A., Zetterberg, H., Passchier, J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1993 · Cited by 74
Bevan-Jones, W. R., Surendranathan, A., Passamonti, L., Rodríguez, P. V., Arnold, R. J., Mak, E., Su, L., Coles, J., Fryer, T. D., Hong, Y. T., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013187 · Cited by 75
Barret, O., Alagille, D., Sanabria, S., Comley, R. A., Weimer, R. M., Borroni, E., Mintun, M. A., Seneca, N. M., Papin, C., Morley, T. J., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.182881 · Cited by 74
Dickstein, D. L., Pullman, M. Y., Fernandez, C., Short, J. A., Kostakoğlu, L., Knešaurek, K., Soleimani, L., Jordan, B. D., Gordon, W. A., Dams-O’Connor, K., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.175 · Cited by 74
Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α‐synuclein pathology
Koga, S., Ono, M., Sahara, N., Higuchi, M., & Dickson, D. W. (2017) · Movement Disorders · doi:10.1002/mds.27013 · Cited by 76
[18F]‐THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy
Brendel, M., Schönecker, S., Höglinger, G., Lindner, S., Havla, J., Blautzik, J., Sauerbeck, J., Rohrer, G., Zach, C., Vettermann, F., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00440 · Cited by 72
Biological applications of near infrared fluorescence dye probes in monitoring Alzheimer’s disease
Gyasi, Y. I., Pang, Y., Li, X., Gu, J.-X., Cheng, X., Liu, J., Xu, T., & Liu, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111982 · Cited by 73
Schoonhoven, D. N., Coomans, E. M., Millán, A. P., van Nifterick, A. M., Visser, D., Ossenkoppele, R., Tuncel, H., van der Flier, W. M., Golla, S. S. V., Scheltens, P., et al. (2023) · Brain · doi:10.1093/brain/awad189 · Cited by 71
Potential Long-Term Consequences of Concussive and Subconcussive Injury
Huber, B. R., Alosco, M. L., Stein, T. D., & McKee, A. C. (2016) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2015.12.007 · Cited by 78
In vivo 18 F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms
Jones, D. T., Knopman, D. S., Graff-Radford, J., Syrjanen, J. A., Senjem, M. L., Schwarz, C. G., Dheel, C., Wszolek, Z., Rademakers, R., Kantarci, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005117 · Cited by 71
Neuroinflammation is linked to dementia risk in Parkinson’s disease
Kouli, A., Spindler, L. R. B., Fryer, T. D., Hong, Y. T., Malpetti, M., Aigbirhio, F. I., White, S. R., Camacho, M., O'Brien, J. T., & Williams‐Gray, C. H. (2023) · Brain · doi:10.1093/brain/awad322 · Cited by 72
Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers
Shah, M., & Catafau, A. M. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.136069 · Cited by 72
Xiong, H., Hoye, A. T., Fan, K., Li, X., Clemens, J., Horchler, C. L., Lim, N. C., & Attardo, G. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b01703 · Cited by 69
Koychev, I. G., on behalf of the Deep and Frequent Phenotyping study team (http://www.dementiastudy.co.uk/), Gunn, R. N., Firouzian, A., Lawson, J., Zamboni, G., Ridha, B. H., Sahakian, B. J., Rowe, J. B., Thomas, A. J., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170129 · Cited by 67
Gandy, S., Ikonomović, M. D., Mitsis, E. M., Elder, G. A., Ahlers, S. T., Barth, J. T., Stone, J. R., & DeKosky, S. T. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-37 · Cited by 68
Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions
Villemagne, V. L., & Okamura, N. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.09.002 · Cited by 70
Advances in the development of tau PET radiotracers and their clinical applications
Okamura, N., Harada, R., Furukawa, K., Furumoto, S., Tago, T., Yanai, K., Arai, H., & Kudo, Y. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2015.12.010 · Cited by 68
Riccardi, C., Napolitano, F., Montesarchio, D., Sampaolo, S., & Melone, M. A. B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111897 · Cited by 70
Imaging Biomarkers Associated With Cognitive Decline: A Review
McConathy, J., & Sheline, Y. I. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.08.024 · Cited by 68
Antibody-DerivedIn VivoImaging of Tau Pathology
Krishnaswamy, S., Lin, Y., Rajamohamedsait, W. J., Rajamohamedsait, H. B., Krishnamurthy, P., & Sigurdsson, E. M. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2755-14.2014 · Cited by 62
Tau and atrophy: domain-specific relationships with cognition
Initiative, A. D. N., Digma, L. A., Madsen, J. R., Reas, E. T., Dale, A. M., Brewer, J. B., & Banks, S. J. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0518-8 · Cited by 66
Ma, S., Chen, G., Xu, J., Liu, Y., Li, G., Chen, T., Li, Y., & James, T. D. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213553 · Cited by 63
Self-citationTauopathy in veterans with long-term posttraumatic stress disorder and traumatic brain injury
Mohamed, A. Z., Cumming, P. D., Götz, J., & Nasrallah, F. A. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4241-7 · Cited by 68
Liu, M., Paranjpe, M. D., Zhou, X., Duy, P. Q., Goyal, M. S., Benzinger, T. L. S., Lu, J., Wang, R., & Zhou, Y. (2019) · Theranostics · doi:10.7150/thno.35366 · Cited by 67
Giacomelli, C., Daniele, S., & Martini, C. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.01.017 · Cited by 71
PET imaging of tau protein targets: a methodology perspective
Lois, C., González, I., Johnson, K. A., & Price, J. C. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-018-9847-7 · Cited by 64
Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy
Ishiki, A., Harada, R., Kai, H., Sato, N., Totsune, T., Tomita, N., Watanuki, S., Hiraoka, K., Ishikawa, Y., Funaki, Y., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0556-7 · Cited by 63
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
Ossenkoppele, R., & Hansson, O. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12356 · Cited by 62
Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies
Maschio, C., & Ni, R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.838034 · Cited by 68
Mitochondrial disorders leading to Alzheimer’s disease—perspectives of diagnosis and treatment
Pszczołowska, M., Walczak, K., Miśków, W., Mroziak, M., Chojdak-Łukasiewicz, J., & Leszek, J. (2024) · GeroScience · doi:10.1007/s11357-024-01118-y · Cited by 65
Comparison of New Tau PET-Tracer Candidates With [ 18 F]T808 and [ 18 F]T807
Declercq, L., Celen, S., Lecina, J., Ahamed, M., Tousseyn, T., Moechars, D., Alcázar, J., Ariza, M., Fierens, K., Bottelbergs, A., et al. (2016) · Molecular Imaging · doi:10.1177/1536012115624920 · Cited by 63
Amyloid imaging, Risk Disclosure and Alzheimer’s Disease: Ethical and Practical Issues
Roberts, J. S., Dunn, L. B., & Rabinovici, G. D. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.25 · Cited by 64
Developments in Tau PET Imaging
Zimmer, E. R., Leuzy, A., Gauthier, S., & Rosa-Neto, P. (2014) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2014.15 · Cited by 60
Nerella, S. G., Joshi, R. K., Bharath, R. D., & Kumar, P. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111979 · Cited by 60
International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease
Tian, M., Civelek, A. C., Carrió, I., Watanabe, Y., Kang, K. W., Murakami, K., Garibotto, V., Prior, J. O., Barthel, H., Zhou, R., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05673-w · Cited by 62
Characterizing the emergence of amyloid and tau burden in Down syndrome
Zammit, M. D., Betthauser, T. J., McVea, A. K., Laymon, C. M., Tudorascu, D. L., Johnson, S. C., Hartley, S. L., Converse, A. K., Minhas, D. S., Zaman, S. H., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13444 · Cited by 60
In Vivo Comparison of Tau Radioligands 18F-THK-5351 and 18F-THK-5317
Betthauser, T. J., Lao, P. J., Murali, D., Barnhart, T. E., Furumoto, S., Okamura, N., Stone, C. K., Johnson, S. C., & Christian, B. T. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.182980 · Cited by 62
Ghirelli, A., Tosakulwong, N., Weigand, S. D., Clark, H. M., Ali, F., Botha, H., Duffy, J. R., Utianski, R. L., Buciuc, M., Murray, M. E., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25893 · Cited by 59
Agüero, C., Dhaynaut, M., Amaral, A. C. S., Moon, S., Neelamegam, R., Scapellato, M., Carazo-Casas, C., Kumar, S., Fakhri, G. E., Johnson, K. A., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02672-z · Cited by 55
Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology
Hahn, A., Schain, M., Erlandsson, M., Sjölin, P., James, G. M., Strandberg, O. T., Hägerström, D., Lanzenberger, R. R., Jögi, J., Olsson, T. G., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.174508 · Cited by 57
Lu, M., Pontecorvo, M. J., Devous, M. D., Arora, A. K., Galante, N., McGeehan, A., Devadanam, C., Salloway, S. P., Doraiswamy, P. M., Curtis, C., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.5505 · Cited by 56
Jang, Y. K., Lyoo, C. H., Park, S., Oh, S. J., Cho, H., Oh, M., Ryu, Y. H., Choi, J. Y., Rabinovici, G. D., Kim, H. J., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3876-0 · Cited by 58
Positron emission tomography imaging of tau pathology in progressive supranuclear palsy
Coakeley, S., Cho, S. S., Koshimori, Y., Rusjan, P., Harris, M., Ghadery, C., Kim, J., Lang, A. E., Wilson, A. A., Houle, S., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16683695 · Cited by 58
From Companion Diagnostics to Theranostics: A New Avenue for Alzheimer’s Disease?
Bolognesi, M. L., Gandini, A., Prati, F., & Uliassi, E. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00151 · Cited by 54
Tau accumulation and its spatial progression across the Alzheimer’s disease spectrum
St‐Onge, F., Chapleau, M., Breitner, J. C. S., Villeneuve, S., Binette, A. P., & Initiative, T. A. D. N. (2023) · Brain Communications · doi:10.1093/braincomms/fcae031 · Cited by 57
Imaging Alzheimer's disease pathophysiology with PET
Schilling, L. P., Zimmer, E. R., Shin, M., Leuzy, A., Pascoal, T. A., Benedet, A. L., Borelli, W. V., Palmini, A., Gauthier, S. G., & Rosa‐Neto, P. (2016) · Dementia & Neuropsychologia · doi:10.1590/s1980-5764-2016dn1002003 · Cited by 57
Seo, Y., Park, K., Ha, T., Kim, M. K., Hwang, Y. J., Lee, J.-H., Ryu, H., Choo, H., & Chong, Y. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00174 · Cited by 52
MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding
Hansen, A. K., Brooks, D. J., & Borghammer, P. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1143-1 · Cited by 51
Silva, M. C., Nandi, G., Donovan, K. A., Cai, Q., Berry, B. C., Nowak, R. P., Fischer, E. S., Gray, N. S., Ferguson, F. M., & Haggarty, S. J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.801179 · Cited by 51
Groot, C., Smith, R. A., Stomrud, E., Binette, A. P., Leuzy, A., Wuestefeld, A., Wisse, L. E. M., Palmqvist, S., Mattsson, N., Janelidze, S., et al. (2022) · Brain · doi:10.1093/brain/awac329 · Cited by 53
Kotzbauer, P. T., Tu, Z., & Mach, R. H. (2016) · Clinical and Translational Imaging · doi:10.1007/s40336-016-0217-4 · Cited by 53
Metadata
- Authors
- Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., Mu, F., Sinha, A., Su, H., Szardenings, A. K., Walsh, J. C., Wang, E., Yu, C., Zhang, W., Zhao, T., & Kolb, H. C.
- Affiliations
- Siemens Healthcare (United States) (US)
- Corresponding author
- Kolb, Hartmuth C.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2013-02-13
- Volume
- 9
- Issue
- 6
- Pages
- 666-676
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W1974444040
- Cited by
- 605
- References
- 41
- Citations by year
- 2026: 23 · 2025: 36 · 2024: 30 · 2023: 37 · 2022: 43 · 2021: 47 · 2020: 45 · 2019: 53 · 2018: 63 · 2017: 80 · 2016: 68 · 2015: 42 · 2014: 30 · 2013: 8
- FWCI
- 34.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Animals, Autoradiography, Brain, Female, Fluorine Radioisotopes, Humans, Male, Mice, Transgenic, Middle Aged, Protein Binding, Tissue Distribution, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
